Shattuck Labs Inc
STTK
Market Cap$503.56M
Close$
$1.85
83.4% downside
Current Fair Value
83.4% downsideOvervalued by 83.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $503.56 Million |
|---|---|
| Enterprise Value | $376.34 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.05 |
| Beta | 0.0 |
| Outstanding Shares | 47,550,872 |
| Avg 30 Day Volume | 271,679 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.77 |
|---|---|
| PEG | 18.98 |
| Price to Sales | - |
| Price to Book Ratio | 3.7 |
| Enterprise Value to Revenue | 227.12 |
| Enterprise Value to EBIT | -4.09 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
ESG Score
No data
About Shattuck Labs Inc
59 employeesShattuck Labs, Inc. operates as a clinical-stage biotechnology company . The Company focuses on developing a novel class of biologic medicines for the treatment of cancer and autoimmune diseases. Shattuck Labs serves customers in the State of Texas.